GYRE
Gyre Therapeutics, Inc.
GYRE trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over GYRE overall, supported by stronger fundamentals and lower modeled downside.
GYRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
GYRE's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
GYRE PE Valuation
GYRE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
GYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect GYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over GYRE on the outlook, with more favorable earnings and profitability expectations.
GYRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.05 | +$2.86 |
| Q3 2024 | -$1.26 | +$19.44 |
| Q2 2024 | -$1.87 | +$20.63 |
| Q1 2024 | -$2.93 | -193% |
| Q4 2023 | -$2.81 | +$1.09 |
| Q3 2023 | -$20.70 | -463% |
| Q2 2023 | -$22.50 | -$18.60 |
| Q1 2023 | $3.15 | +$41.25 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 114% for GYRE versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
GYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.9M | +7.8% |
| Q2 2026 | $29.1M | +8.7% |
| Q1 2026 | $22.5M | +2.1% |
| Q4 2025 | $37.2M | +33% |
| Q3 2025 | $30.6M | +20% |
| Q2 2025 | $26.8M | +6.1% |
| Q1 2025 | $22.1M | -19% |
| Q1 2022 | $794K | -46% |
GYRE's revenue has grown year over year for six quarters in a row: $33M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | -27 points |
| Q2 2026 | -49% | -58 points |
| Q1 2026 | -42% | -52 points |
| Q4 2025 | 0.3% | -1.8 points |
| Q3 2025 | 23% | +6.1 points |
| Q2 2025 | 8.1% | -4.8 points |
| Q1 2025 | 10% | -19 points |
| Q4 2024 | 2.1% | N/A |
GYRE's operating margin was −4.6% last quarter, down 27 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over GYRE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over GYRE on profitability, with a higher operating margin.
GYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | -224% |
| Q2 2026 | -$17M | -1027% |
| Q1 2026 | $3M | +$3.3M |
| Q4 2025 | -$5.8M | -$3.1M |
| Q3 2025 | $4M | +288% |
| Q2 2025 | $1.8M | +$8.8M |
| Q1 2025 | -$251K | -109% |
| Q3 2024 | $1M | +$4.3M |
GYRE has burned cash in most quarters: −$25M over the past year, against $3M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over GYRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +5.7M shares |
| 1 year | +2.2% | +2.3M shares |
| 3 years | +4955% | +104M shares |
| 5 years | +7124% | +105M shares |
GYRE has 106M diluted shares, up 2.2% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over GYRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
GYRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q1 2023 | -1.3x | Net Cash |
| Q3 2022 | -2.0x | Net Cash |
GYRE has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
GYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 10.3 | Oversold |
GYRE's weekly RSI is 32 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
GYRE PE vs Healthcare Sector
| Metric | GYRE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GYRE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
GYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.88 | 27% below |
| 20 week MA | $6.33 | 32% below |
| 50 week MA | $6.89 | 38% below |
| 100 week MA | $7.91 | 46% below |
| 200 week MA | $9.42 | 54% below |
GYRE is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over GYRE on trend strength, trading above more of its moving averages.
GYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.4 | $97.1 | -4.3% |
| 2021 | $97.1 | $15.9 | -84% |
| 2022 | $15.9 | $7.50 | -53% |
| 2023 | $7.50 | $25.7 | +243% |
| 2024 | $25.7 | $12.5 | -52% |
| 2025 | $12.5 | $7.26 | -42% |
| 2026 YTD | $7.26 | $4.30 | -41% |
GYRE's yearly returns have swung widely, from +243% in 2023 to −84% in 2021. It's down 41% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over GYRE on returns for 2026, with the stronger performance.